Denali Therapeutics' GAAP loss for 3 months of 2021 was $70.041 million, up 23.4% from $56.763 million in the prior year. Revenue increased 2.2-fold to $7.923 million from $3.604 million a year earlier.
Denali Therapeutics' GAAP loss for 3 months of 2021 was $70.041 million, up 23.4% from $56.763 million in the prior year. Revenue increased 2.2-fold to $7.923 million from $3.604 million a year earlier. 
denalitherapeutics.com
English (US) 